clinical trial · NCT00649376
Fasting Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg
HealthyFexofenadine Tablets 180 mgAllegra® Tablets 180 mg
brief summary
The objective of this study was to investigate the bioequivalence of Mylan's fexofenadine 180 mg tablets to Aventis' Allegra® 180 mg tablets following a single, oral 180 mg (1 x 180 mg) dose administered under fasting conditions.
started
Oct 1, 2003
primary completion
Nov 1, 2003
completion
Nov 1, 2003
last updated
Apr 24, 2024
official title
Single-Dose Fasting In Vivo Bioequivalence Study of Fexofenadine Tablets (180 mg; Mylan) and Allegra® Tablets (180 mg; Aventis) in Healthy Adult Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol